Status:
ENROLLING_BY_INVITATION
Validation Study of a New Digital Diagnostic and Treatment Test Based on Interactive Video Games for Alzheimer's Disease
Lead Sponsor:
Braingaze
Conditions:
Alzheimer Disease
MCI
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
This study aims to validate a novel, non-invasive diagnostic and digital therapeutic approach for Alzheimer's Disease (AD), centered on an interactive video game called BGaze Therapy. This platform le...
Eligibility Criteria
Inclusion
- Aged 50 years or older.
- Clinical diagnosis of early-stage AD or MCI based the criteria of National Institute on Aging-Alzheimer's Association.
- Capable of providing informed consent.
Exclusion
- Severe cognitive impairment (MMSE \< 10).
- Neurological conditions affecting cognition (e.g., stroke).
- Severe psychiatric disorders.
- Structural brain abnormalities (e.g., tumors) with cognitive impact.
- Significant visual impairments.
- Inability to understand or communicate in Spanish.
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06963879
Start Date
May 1 2025
End Date
December 31 2025
Last Update
May 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Braingaze
Mataró, Barcelona, Spain, 08302